Feldkamp, M M <br/><br/>
Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.  [electronic resource] 

 -  Cancer research  Jun 2001 
 - 4425-31 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alkyl and Aryl Transferases--antagonists & inhibitors<br/>Animals<br/>Astrocytoma--drug therapy<br/>Brain Neoplasms--drug therapy<br/>Cell Division--drug effects<br/>Enzyme Inhibitors--pharmacology<br/>Farnesyltranstransferase<br/>Genes, ras--genetics<br/>Glioblastoma--drug therapy<br/>Guanosine Triphosphate--metabolism<br/>Humans<br/>Immunohistochemistry<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred NOD<br/>Mice, Nude<br/>Mice, SCID<br/>Monomeric GTP-Binding Proteins--metabolism<br/>Mutation<br/>Piperidines--pharmacology<br/>Pyridines--pharmacology<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays<br/>ras Proteins--genetics